scholarly journals Total protein concentration and T-cell suppression activity of aqueous humour before and after penetrating keratoplasty

Eye ◽  
2011 ◽  
Vol 26 (1) ◽  
pp. 153-158 ◽  
Author(s):  
J-S Mo ◽  
P Maier ◽  
D Böhringer ◽  
H Reinshagen ◽  
R Sundmacher ◽  
...  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Wenxin Wu ◽  
Lili Tian ◽  
Wei Zhang ◽  
J. Leland Booth ◽  
Erola Ainsua-Enrich ◽  
...  

Abstract Background Influenza is a highly contagious, acute, febrile respiratory infection caused by a negative-sense, single-stranded RNA virus, which belongs in the Orthomyxoviridae family. Cigarette smoke (CS) exposure worsens influenza infection in terms of frequency and severity in both human and animal models. Methods C57BL/6 mice with or without CS exposure for 6 weeks were inoculated intranasally with a single, non-lethal dose of the influenza A virus (IAV) A/Puerto Rico/8/1934 (PR8) strain. At 7 and 10 days after infection, lung and mediastinal lymph nodes (MLN) cells were collected to determine the numbers of total CD4 + and CD8 + T cells, and IAV-specific CD4 + and CD8 + T cells, using flow cytometry. Bronchoalveolar lavage fluid (BALF) was also collected to determine IFN-γ levels and total protein concentration. Results Although long-term CS exposure suppressed early pulmonary IAV-antigen specific CD8 + and CD4 + T cell numbers and IFN-γ production in response to IAV infection on day 7 post-infection, CS enhanced numbers of these cells and IFN-γ production on day 10. The changes of total protein concentration in BALF are consistent with the changes in the IFN-γ amounts between day 7 and 10, which suggested that excessive IFN-γ impaired barrier function and caused lung injury at the later stage of infection. Conclusions Our results demonstrated that prior CS exposure caused a biphasic T cell and IFN-γ response to subsequent infection with influenza in the lung. Specifically, the number of IAV antigen-specific T cells on day 10 was greatly increased by CS exposure even though CS decreased the number of the same group of cells on day 7. The result suggested that CS affected the kinetics of the T cell response to IAV, which was suppressed at an early stage and exaggerated at a later stage. This study is the first to describe the different effect of long-term CS on T cell responses to IAV at early and late stages of infection in vivo.


2021 ◽  
Author(s):  
Go Itoh ◽  
Kurara Takagane ◽  
Yuma Fukushi ◽  
Sei Kuriyama ◽  
Michinobu Umakoshi ◽  
...  

Rheumatology ◽  
2015 ◽  
Vol 55 (4) ◽  
pp. 710-720 ◽  
Author(s):  
Michael Bonelli ◽  
Lisa Göschl ◽  
Stephan Blüml ◽  
Thomas Karonitsch ◽  
Kiyoshi Hirahara ◽  
...  

2014 ◽  
Vol 27 (1) ◽  
pp. 253-257 ◽  
Author(s):  
Patrick Marcel Seumo Tchekwagep ◽  
Charles Péguy Nanseu-Njiki ◽  
Emmanuel Ngameni ◽  
Ravi Danielsson ◽  
Thomas Arnebrant ◽  
...  

2016 ◽  
Vol 11 (10) ◽  
pp. 1755-1764 ◽  
Author(s):  
Lysanne A. Lievense ◽  
Robin Cornelissen ◽  
Koen Bezemer ◽  
Margaretha E.H. Kaijen-Lambers ◽  
Joost P.J.J. Hegmans ◽  
...  

2017 ◽  
Vol 8 (2) ◽  
pp. e2632-e2632 ◽  
Author(s):  
Hyun Seung Yoo ◽  
Kyuheon Lee ◽  
Kwangmin Na ◽  
Yong Xu Zhang ◽  
Hyun-Ja Lim ◽  
...  

2021 ◽  
Vol 22 (7) ◽  
pp. 3522
Author(s):  
Alexandra A. Vita ◽  
Hend Aljobaily ◽  
David O. Lyons ◽  
Nicholas A. Pullen

There is evidence that berberine (BBR), a clinically relevant plant compound, ameliorates clinically apparent collagen-induced arthritis (CIA) in vivo. However, to date, there are no studies involving the use of BBR which explore its prophylactic potential in this model of rheumatoid arthritis (RA). The aim of this study was to determine if prophylactic BBR use during the preclinical phase of collagen-induced arthritis would delay arthritic symptom onset, and to characterize the cellular mechanism underlying such an effect. DBA/1J mice were injected with an emulsion of bovine type II collagen (CII) and complete Freund’s adjuvant (day 0) and a booster injection of CII in incomplete Freund’s adjuvant (day 18) to induce arthritis. Mice were then given i.p. injections of 1 mg/kg/day of BBR or PBS (vehicle with 0.01% DMSO) from days 0 to 28, were left untreated (CIA control), or were in a non-arthritic control group (n = 15 per group). Incidence of arthritis in BBR-treated mice was 50%, compared to 90% in both the CIA and PBS controls. Populations of B and T cells from the spleens and draining lymph nodes of mice were examined on day 14 (n = 5 per group) and day 28 (n = 10 per group). BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints. The effect seen on T cell populations and co-stimulatory molecule expression in BBR-treated mice was not mirrored in CD19+ B cells. Additionally, BBR-treated mice experienced reduced anti-CII IgG2a and anti-CII total IgG serum concentrations. These results indicate a potential role for BBR as a prophylactic supplement for RA, and that its effect may be mediated specifically through T cell suppression. However, the cellular effector involved raises concern for BBR prophylactic use in the context of vaccine efficacy and other primary adaptive immune responses.


Sign in / Sign up

Export Citation Format

Share Document